Subgroup findings boost ribociclib-letrozole potential in Asians with HR+, HER2– advanced breast cancer
26 Nov 2020
byAudrey Abella
In a subgroup analysis of the phase IIIb CompLEEment-1 trial, ribociclib plus letrozole showed a manageable safety profile in Asian patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC).
Subgroup findings boost ribociclib-letrozole potential in Asians with HR+, HER2– advanced breast cancer
26 Nov 2020